Patent SG-11201907207U-A (SG)
Title: Pharmaceutical combinations comprising an anti-ly75 antibody
Inventor: BINASCHI MONICA
IPC: C07K16/46
Filed: 2018-03-09
Abstract: HBL14V , O cs\"<\" s. (5 0 1-1 N N N N 1-1 00 O 1-1 N C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIP0 I PCT ~~ll~~~~~~~~ 011101010VIIIOH olo VIIIVIII0100111010m 1111101 ois (10) International Publication Number WO 2018/162727 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 47/68 (2017.01) A61P 35/00 (2006.01) A61K 31/505 (2006.01) A61P 35/02 (2006.01) CO7K 16/46 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/EP2018/055939 (22) International Filing Date: 09 March 2018 (09.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1703876.1 10 March 2017 (10.03.2017) GB (71) Applicant: BERLIN-CHEMIE AG [DE/DE]; Glienicker Weg 125-127, 12489 Berlin (DE). (72) Inventors: BINASCHI, Monica; Menarini Ricerche, Via Tito Speri 10 Pomezia, Rome (IT). BIGIONI, Mario; Menarini Ricerche, Via Tito Speri 10 Pomezia, Rome (IT). MERLINO, Giuseppe; Menarini Ricerche, Via Tito Speri 10 Pomezia, Rome (IT). SIMONELLI, Cecilia; Menari- ni Ricerche, Via Sette Santi 3, Firenze (IT). BERTONI, Francesco; Institute of Oncology Research Fondazione per la Ricerca e la Cura sui Linfomi, Via Vela 6, 6500 Bellinzona (CH). PELLACANI, Andrea; Menarini Ricerche, Via Sette Santi 3, Firenze (IT). (74) Agent: DEHNS; St Bride's House, 10 Salisbury Square, London, Greater London EC4Y 8JD (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY Figure 9 IBRUTINIB (nM) II 0 III 15,625 MI 31,25 MI 62,5 MI 126 L 250 M. 500 1000 ma urn LY75_DM4 (nM) (57) : The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity. [Continued on next page] WO 2018/162727 Al MIDEDIMOMMIDIREEMOMOHEIDEMIHOEHMEMOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))